NuVasive valuation remains compelling, says Barrington

Barrington raised its price target for NuVasive shares to $42 and says the stock remains one of its top ideas following the company's Q3 results. The firm says the stock's valuation remains "very compelling" at current levels and keeps an Outperform rating on the name.

Advertisement